Skip to main content
SpringerLink
Log in

Adoptive Immunotherapy Using Donor Leukocyte Infusions to Treat Relapsed Hematologic Malignancies after Allogeneic Bone Marrow Transplantation

  • Chapter
Advances in Allogeneic Hematopoietic Stem Cell Transplantation

Part of the book series: Cancer Treatment and Research ((CTAR,volume 101))

Abstract

Allogeneic bone marrow transplantation (BMT) is the only curative therapy for a number of patients with hematologic malignancies. The therapeutic efficacy of allogeneic marrow transplantation derives from the conditioning regimen which is myeloablative and the allogeneic marrow graft itself which is able to exert an antileukemic effect against residual malignant cell populations. This phenomenon which has been termed the graft-versus-leukemia (GVL) effect is mediated by immunocompetent cells resident in the donor marrow graft (1). Support for the existence of the GVL effect has come from both animal models (2,3) and epidemiological studies in man (4) which have provided strong evidence that allogeneic marrow transplantation is a potent demonstration of effective adoptive immunotherapy.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 169.00
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 219.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 219.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Gale RP, Champlin RE. How does bone-marrow transplantation cure leukaemia? The Lancet, 1984; 2: 28–30.

    Article  CAS  Google Scholar 

  2. Bortin MM, Truitt RL, Rimm AA, Bach FH. Graft-versus-leukaemia reactivity induced by alloimmunisation without augmentation of graft-versus-host reactivity. Nature, 1979; 281: 490–491.

    Article  PubMed  CAS  Google Scholar 

  3. Truitt RL, Shih CCY, LeFever AV. Manipulation of graft-versus-host disease for a graft-versus-leukemia effect after allogeneic bone marrow transplantation in AKR mice with spontaneous leukemia/lymphoma. Transplantation, 1986; 41: 301–310.

    Article  PubMed  CAS  Google Scholar 

  4. Horowitz MM, Gale RP, Sondel PM, Goldman JM, Kersey J, Kolb HJ, Rimm AA, Ringden O, Rozman C, Speck B, Truitt RL, Zwaan FE, Bortin MM. Graft-versus-leukemia reactions after bone marrow transplantation. Blood, 1990; 75: 555–562.

    PubMed  CAS  Google Scholar 

  5. Sullivan KM, Weiden PL, Storb R, Witherspoon RP, Fefer A, Fisher L, Buckner CD, Anasetti C, Appelbaum FR, Badger C, Beatty P, Bensinger W, Berenson R, Bigelow C, Cheever MA, Clift R, Deeg HJ, Doney K, Greenberg P, Hansen JA, Hill R, Loughran T, Martin P, Neiman P, Petersen FB, Sanders J, Singer J, Stewart P, Thomas ED. Influence of acute and chronic graft-versus-host disease on relapse and survival after bone marrow transplantation from HLA-identical siblings as treatment of acute and chronic leukemia. Blood, 1989; 73: 1720–1728.

    PubMed  CAS  Google Scholar 

  6. Sullivan KM, Storb R, Buckner D, Fefer A, Fisher L, Weiden PL, Witherspoon RP, Appelbaum FR, Banaji M, Hansen J, Martin P, Sanders JE, Singer J, Thomas ED. Graft-versus-host disease as adoptive immunotherapy in patients with advanced hematologic neoplasms. The New England Journal of Medicine, 1989; 320,13: 828–834.

    Article  PubMed  CAS  Google Scholar 

  7. Vos O, Weyzen WWH. “Killing effect” of injected lymph node cells in homologous radiation chimeras. Transplantation Bulletin, 1962; 30: 501.

    Article  Google Scholar 

  8. Thompson JS, Simmons EL, Moy RH, Crawford MK. Studies on immunologic unresponsiveness during secondary disease. The Journal of Immunology, 1967;98, 1: 179–185.

    PubMed  CAS  Google Scholar 

  9. Weiden PL, Storb R, Tsoi MS, Graham TC, Lerner KG, Thomas ED. Infusion of donor lymphocytes into stable canine radiation chimeras: implications for mechanism of transplantation tolerance. The Journal of Immunology, 1976; 116,5: 1212–1219.

    PubMed  CAS  Google Scholar 

  10. Kolb HJ, Mittermuller J, Clemm C, Holler E, Ledderose G, Brehm G, Heim M, Wilmanns W. Donor leukocyte transfusions for treatment of recurrent chronic myelogenous leukemia in marrow transplant patients. Blood, 1990; 76, 12: 2462–2465.

    PubMed  CAS  Google Scholar 

  11. Slavin S, Or R, Naparstek E, Eckerstein A, Weiss L. Cellular-mediated immunotherapy of leukemia in conjunction with autologous and allogeneic bone marrow transplantation in experiment animals and man. Blood, 1988; 72: 407a.

    Google Scholar 

  12. Johnson BD, Drobyski WR, Truitt RL. Delayed infusion of normal donor cells after MHC-matched bone marrow transplantation provides an antileukemia reaction without graft-versus-host disease. Bone Marrow Transplantation, 1993; 11: 329–336.

    PubMed  CAS  Google Scholar 

  13. Van Bekkum DW, Kinwel-Bohre EPM. Risk of donor lymphocyte infusions following allogeneic bone marrow transplantation. Experimental Hematology, 1997; 25: 478–480.

    PubMed  Google Scholar 

  14. Johnson BD, Truitt RL. Delayed infusion of immunocompetent donor cells after bone marrow transplantation breaks graft-host tolerance and allows for persistent antileukemic reactivity without severe graft-versus-host disease. Blood, 1995; 85,11: 3302–3312.

    PubMed  CAS  Google Scholar 

  15. Blazar BR, Taylor PA, Boyer MW, Panoskaltsis-Mortari A, Allison JP, Vallera DA.. CD28/B7 interactions are required for sustaining the graft-versus-leukemia effect of delayed post-bone marrow transplantation splenocyte infusion in murine recipients of myeloid or lymphoid leukemia cells. The Journal of Immunology, 1997; 159: 3460–3473.

    PubMed  CAS  Google Scholar 

  16. Papadopoulos EB, Ladanyi M, Emanuel D, Mackinnon S, Boulad F, Carabasi MH, Castro-Malaspina H, Childs BH, Gillio AP, Small TN, Young JW, Kernan NA, O’Reilly RJ. Infusions of donor leukocytes to treat Epstein-Barr virus-associated lymphoproliferative disorders after allogeneic bone marrow transplantation. New England Journal of Medicine, 1994; 330: 1185–1191.

    Article  PubMed  CAS  Google Scholar 

  17. Collins Jr. RH, Shpilberg O, Drobyski WR, Porter DL, Giralt S, Champlin R, Goodman SA, Wolff SN, Hu W, Verfaillie C, List A, Dalton W, Ognoskie N, Chetrit A, Antin JH, Nemunaitis J. Donor leukocyte infusions in 140 patients with relapsed malignancy after allogeneic bone marrow transplantation. Journal of Clinical Oncology, 1997; 15,2: 433–444.

    PubMed  Google Scholar 

  18. Kolb HJ, Schattenberg A, Goldman JM, Hertenstein B, Jacobsen N, Arcese W, Ljungman P, Ferrant A, Verdonck L, Niederwieser D, van Rhee F, Mittermueller J, de Witte T, Holler E, Ansari H. Graft-versus-leukemia effect of donor lymphocyte transfusions in marrow grafted patients. Blood, 1995; 86: 2041–2050.

    PubMed  CAS  Google Scholar 

  19. Drobyski W, Keever C, Roth M, Koethe S, Hanson G, McFadden P, Gottschall J, Ash R, Van Tuinen P, Horowitz M, Flomenberg N. Salvage immunotherapy using donor leukocyte infusions as treatment for relapsed chronic myelogenous leukemia after allogeneic bone marrow transplantation: Efficacy and toxicity of a defined T-cell dose. Blood, 1993;82: 2310–2318.

    PubMed  CAS  Google Scholar 

  20. Hertenstein B, Wiesneth M, Novotny J, Bunjes D, Stefanic M, Heinze B, Hubner G, Heimpel, H, Arnold R. Interferon-oc and donor buffy coat transfusions for treatment of relapsed chronic myeloid leukemia after allogeneic bone marrow transplantation. Transplantation, 1993; 56: 1114–1118.

    Article  PubMed  CAS  Google Scholar 

  21. Bar BM, Schattenberg A, Mensink EJBM, Van Kessel G, Smetsers TFCM, Knops GHJN, Linders EHP, De Witte T. Donor leukocyte infusions for chronic myeloid leukemia relapsed after allogeneic bone marrow transplantation. Journal of Clinical Oncology; 1993; 11,3: 513–519.

    PubMed  CAS  Google Scholar 

  22. Helg C, Roux E, Beris P, Cabrol C, Wacker P, Darbellay R, Wyss M, Jeannet M, Chapuis B, Roosnek E: Adoptive immunotherapy for recurrent CML after BMT. Bone Marrow Transplantation, 1993; 12: 125–129.

    PubMed  CAS  Google Scholar 

  23. Porter DL, Roth MS, McGarigle C, Ferrara JLM, Antin JH. Induction of graft-versus-host disease as immunotherapy for relapsed chronic myeloid leukemia. The New England Journal of Medicine, 1994; 330, 2: 100–106.

    Article  PubMed  CAS  Google Scholar 

  24. Cullis JO, Jiang YZ, Schwarer AP, Hughes TP, Barrett AJ, Goldman JM. Donor leukocyte infusions for chronic myeloid leukemia in relapse after allogeneic bone marrow transplantation. Blood, 1992;79: 1379–1381.

    PubMed  CAS  Google Scholar 

  25. Raanani P, Dazzi F, Sohal J, Szydlo RM, van Rhee F, Reiter A, Lin F, Goldman JM, Cross NCP. The rate and kinetics of molecular response to donor leucocyte transfusions in chronic myeloid leukaemia patients treated for relapse after allogeneic bone marrow transplantation. British Journal of Haematology, 1997; 99: 945–950.

    Article  PubMed  CAS  Google Scholar 

  26. van Rhee F, Lin F, Cullis JO, Spencer A, Cross NCP, Chase A, Garicochea B, Bungey J, Barrett J, Goldman JM. Relapse of chronic myeloid leukemia after allogeneic bone marrow transplant: The case for giving donor leukocyte transfusions before the onset of hematologic relapse. Blood, 1994, 83: 3377–3383.

    PubMed  Google Scholar 

  27. Mackinnon S, Papadopoulos EB, Carabasi MH, Reich L, Collins NH, Boulad F, Castro-Malaspina H, Childs BH, Gillio AP, Kernan NA, Small TN, Young JW, O’Reilly RJ. Adoptive immunotherapy evaluating escalating doses of donor leukocytes for relapse of chronic myeloid leukemia after bone marrow transplantation: separation of graft-versus-leukemia responses from graft-versus-host disease. Blood, 1995; 86: 1261–1268.

    PubMed  CAS  Google Scholar 

  28. Alyea EP, Soiffer RJ, Canning C, Neuberg D, Schlossman R, Pickett C, Collins H, Wang Y, Anderson KC, Ritz J. Toxicity and efficacy of defined doses of CD4+ donor lymphocytes for treatment of relapse after allogeneic bone marrow transplant. Blood; 91: 3671–3680.

    Google Scholar 

  29. Mehta J, Powles R, Singhal S, Tait D, Swansbury J, Treleaven J. Cytokine-mediated immunotherapy with or without donor leukocytes for poor-risk acute myeloid leukemia relapsing after allogeneic bone marrow transplantation. Bone Marrow Transplantation, 1995; 16: 133–137.

    PubMed  CAS  Google Scholar 

  30. Porter DL, Roth MS, Lee SJ, McGarigle C, Ferrara JLM, Antin JH. Adoptive immunotherapy with donor mononuclear cell infusions to treat relapse of acute leukemia or myelodysplasia after allogeneic bone marrow transplantation. Bone Marrow Transplantation, 1996; 18: 975–980.

    PubMed  CAS  Google Scholar 

  31. Mehta J, Powles R, Kulkarni S, Treleaven J, Singhal S. Induction of graft-versus-host disease as immunotherapy of leukemia relapsing after allogeneic transplantation: single-center experience of adult patients. Bone Marrow Transplantation, 1997; 20: 129–135.

    Article  PubMed  CAS  Google Scholar 

  32. Glass B, Majolino I, Dreger P, Scime R, Santoro A, Vasta S, Suttorp M, Haferlach T, Schmitz N. Allogeneic peripheral blood progenitor cells for treatment of relapse after bone marrow transplantation. Bone Marrow Transplantation, 1997; 20: 533–541.

    Article  PubMed  CAS  Google Scholar 

  33. Atra A, Millar B, Shepherd V, Shankar A, Wilson K, Treleaven J, Pritchard-Jones K, Meller ST, Pinkerton CR. Donor lymphocyte infusion for childhood acute lymphoblastic leukaemia relapsing after bone marrow transplantation. British Journal of Haematology, 1997; 97: 165–168.

    Article  PubMed  CAS  Google Scholar 

  34. Cardoso AA, Schultze JL, Boussiotis VA, Freeman GJ, Seamon MJ, Laszlo S, Billet A, Sallan SE, Gribben JG, Nadler LM. Pre-B acute lymphoblastic leukemia cells may induce T-cell anergy to alloantigen. Blood, 1996; 88: 41–48.

    PubMed  CAS  Google Scholar 

  35. Verdonck LF, Lokhorst HM, Dekker AW, Nieuwenhuis HK, Petersen EJ. Graft-versus-myeloma effect in two cases. The Lancet, 1996; 347: 800–801.

    Article  CAS  Google Scholar 

  36. Tricot G, Vesole DH, Jagannath S, Hilton J, Munshi N, Barlogie B. Graft-versus-myeloma effect: Proof of principle. Blood, 1996; 87: 1196–1198.

    PubMed  CAS  Google Scholar 

  37. Lokhorst MH, Schattenberg A, Cornelissen JJ, Thomas LLM, Verdonck LF. Donor leukocyte infusions are effective in relapsed multiple myeloma after allogeneic bone marrow transplantation. Blood, 1997; 90: 4206–4211.

    PubMed  CAS  Google Scholar 

  38. Bertz H, Burger JA, Kunzmann R, Mertelsmann R, Finke J. Adoptive immunotherapy for relapsed multiple myeloma after allogeneic bone marrow transplantation (BMT): evidence for a graft-versus-myeloma effect. Leukemia, 1997; 11; 281–283.

    Article  PubMed  CAS  Google Scholar 

  39. Van Besien KW, De Lima M, Giralt SA, Moore Jr DF, Khouri IF, Rondon G, Mehra R, Andersson BS, Dyer C, Cleary K, Przepiorka D, Gajewski JL, Champlin RE. Management of lymphoma recurrence after allogeneic transplantation: the relevance of graft-versus-lymphoma effect. Bone Marrow Transplantation, 1997; 19: 977–982.

    Article  PubMed  Google Scholar 

  40. Russell LA, Jacobsen N, Heilmann C, Simonsen AC, Christensen LD, Vindelov LL. Treatment of relapse after allogeneic BMT with donor leukocyte infusions in 16 patients. Bone Marrow Transplantation, 1996; 18: 411–414.

    PubMed  CAS  Google Scholar 

  41. Slavin S, Naparstek E, Nagler A, Ackerstein A, Samuel S, Kapelushnik J, Brautbar C, Or R. Allogeneic cell therapy with donor peripheral blood cells and recombinant interleukin-2 to treat leukemia relapse after allogeneic bone marrow transplantation. Blood 1996; 87: 2195–2204.

    PubMed  CAS  Google Scholar 

  42. Hill GR, Crawford JM, Cooke KR, Brinson YS, Pan L, Ferrara JLM. Total body irradiation and acute graft-versus-host disease: The role of gastrointestinal damage and inflammatory cytokines. Blood, 1997; 90: 3204–3213.

    PubMed  CAS  Google Scholar 

  43. Bacigalupo A, Soracco M, Vassallo F, Abate M, Van Lint MT, Gualandi F, Lamparelli T, Occhini D, Mordini N, Bregante S, Figari O, Benvenuto F, Sessarego M, Fugazza G, Carlier P, Valbonesi M. Donor lymphocyte infusions (DLI) in patients with chronic myeloid leukemia following allogeneic bone marrow transplantation. Bone Marrow Transplantation, 1997; 927–932.

    Google Scholar 

  44. Anderson KC, Weinstein HJ. Transfusion-associated graft-versus-host disease. New England Journal of Medicine, 1990; 323: 315–321.

    Article  PubMed  CAS  Google Scholar 

  45. Leber B, Walker IR, Rodriguez A, McBride JA, Carter R, Brain MC. Reinduction of remission of chronic myeloid leukemia by donor leukocyte transfusion following relapse after bone marrow transplantation: recovery complicated by initial pancytopenia and late dermatomyositis. Bone Marrow Transplantation, 1993; 12: 405–407.

    PubMed  CAS  Google Scholar 

  46. Rapanotti MC, Arcese W, Buffolino S, Lori AP, Mengarelli A, De Cuia MR, Cardillo A, Cimino, G. Sequential molecular monitoring of chimerism in chronic myeloid leukemia patients receiving donor lymphocyte transfusion for relapse after bone marrow transplantation. Bone Marrow Transplantation, 1997; 19: 703–707.

    Article  PubMed  CAS  Google Scholar 

  47. Keil F, Haas OA, Fritsch G, Kalhs P, Lechner K, Mannhalter C, Reiter E, Niederwieser D, Hoecker P, Greinix HT. Donor leukocyte infusion for leukemic relapse after allogeneic marrow transplantation: Lack of residual donor hematopoiesis predicts aplasia. Blood; 89: 3113–3117.

    Google Scholar 

  48. Keil F, Kalhs P, Haas OA, Fritsch G, Mitterbauer G, Brugger S, Lechner K, Schwarzinger I, Mannhalter C, Linkesch W, Kurz M, Greinix HT. Graft failure after donor leucocyte infusion in relapsed chronic myeloid leukaemia: successful treatment with cyclophosphamide and antithymocyte globulin followed by peripheral blood stem cell infusion. British Journal of Haematology, 1996; 94: 120–122.

    Article  PubMed  CAS  Google Scholar 

  49. Chen W, Peace DJ, Rovira DK, You SG, Cheever MA. T-cell immunity to the joining region of p210BCR-ABL protein. Proceedings of National Academy and Sciences, 1992; 89: 1468–1472.

    Article  CAS  Google Scholar 

  50. Bocchia M, Korontsvit T, Xu Q, Mackinnon S, Yang SY, Sette A, Scheinberg DA. Specific human cellular immunity to bcr-abl oncogene-derived peptides. Blood, 1996; 87: 3587–3592.

    PubMed  CAS  Google Scholar 

  51. Warren EH, Greenberg PD, Riddell SR. Cytotoxic T-lymphocyte-defined human minor histocompatibility antigens with a restricted tissue distribution. Blood, 1998; 91: 2197–2207.

    PubMed  CAS  Google Scholar 

  52. Voogt PJ, Goulmy ELS, Veenhof WFJ, Hamilton M, Fibbe WE, Van Rood JJ, Falkenburg JHF. Cellularly defined minor histocompatibility antigens are differentially expressed on human hematopoietic progenitor cells. Journal of Experimental Medicine, 1988; 168: 2337–2347.

    Article  PubMed  CAS  Google Scholar 

  53. Faber LM, van Luxemburg-Heijs SAP, Willemze R, Falkenburg JHF. Generation of leukemia-reactive cytotoxic T lymphocyte clones from the HLA-identical bone marrow donor of a patient with leukemia. Journal of Experimental Medicine, 1992; 176: 1283–1289.

    Article  PubMed  CAS  Google Scholar 

  54. Marijt WA, Veenhof WFJ, Brand A, Goulmy E, Fibbe WE, Willemze R, Van Rood JJ, Falkenburg JHF. Minor histocompatibility antigen-specific cytotoxic T cell lines, capable of lysing human hematopoietic progenitor cells, can be generated in vitro by stimulation with HLA-identical bone marrow cells. Journal of Experimental Medicine, 1991; 173: 101–109.

    Article  PubMed  CAS  Google Scholar 

  55. Claret EJ, Alyea EP, Orsini E, Pickett CC, Collins H, Wang Y, Neuberg D, Soiffer RJ, Ritz J. Characterization of T cell repertoire in patients with graft-versus-leukemia after donor lymphocyte infusion. Journal of Clinical Investigation, 1997; 100: 855–866.

    Article  PubMed  CAS  Google Scholar 

  56. Jiang YZ, Barrett AJ. Cellular and cytokine-mediated effects of CD4-positive lymphocyte lines generated in vitro against chronic myelogenous leukemia. Experimental Hematology, 1995; 23: 1167–1172.

    PubMed  CAS  Google Scholar 

  57. Champlin R, Ho W, Gajewski J, Feig S, Burnison M, Holley G, Greenberg P, Lee K, Schmid I, Giorgi J, Yam P, Petz, L, Winston D, Warner N, Reichert T. Selective depletion of CD8+ T lymphocytes for prevention of graft-versus-host disease after allogeneic bone marrow transplantation. Blood, 1990;76: 418–423.

    PubMed  CAS  Google Scholar 

  58. Smit WM, Rijnbeek M, Van Bergen CAM, Willemze R, Falkenburg JHF. Generation of leukemia-reactive cytotoxic T lymphocytes from HLA-identical donors of patients with chronic myeloid leukemia using modifications of a limiting dilution assay. Bone Marrow Transplantation, 1998;21: 553–560.

    Article  PubMed  CAS  Google Scholar 

  59. Jiang YZ, Cullis JO, Kanfer EJ, Goldman JM, Barrett AJ. T cell and NK cell mediated graft-versus-leukaemia reactivity following donor buffy coat transfusion to treat relapse after marrow transplantation for chronic myeloid leukaemia. Bone Marrow Transplantation, 1993; 11: 133–138.

    PubMed  CAS  Google Scholar 

  60. Goldman JM, Gale RP, Horowitz MM, Biggs JC, Champlin RE, Gluckman E, Hoffmann, RG, Jacobsen SJ, Marmont AM, McGlave PB, Messner HA, Rimm AA, Rozman C, Speck B, Tura S, Weiner RS, Bortin MM. Bone marrow transplantation for chronic myelogenous leukemia in chronic phase: Increased risk of relapse associated with T-cell depletion. Annals Internal Medicine, 1988; 108: 806–814.

    CAS  Google Scholar 

  61. Mackinnon S, Papadopoulos EB, Carabasi MH, Reich L, Collins NH: O’Reilly RJ. Adoptive immunotherapy using donor leukocytes following bone marrow transplantation for chronic myeloid leukemia: is T cell dose important in determining biological response? Bone Marrow Transplantation, 1995; 15: 591–594.

    PubMed  CAS  Google Scholar 

  62. Van Rhee F, Savage D, Blackwell J, Orchard K, Dazzi F, Lin F, Chase A. Bungey J, Cross NCP, Apperley J, Szydlo R, Goldman JM. Adoptive immunotherapy for relapse of chronic myeloid leukemia after allogeneic bone marrow transplant: equal efficacy of lymphocytes from sibling and matched unrelated donors. Bone Marrow Transplantation, 1998; 21: 1055–1061.

    Article  PubMed  Google Scholar 

  63. Pati AR, Godder K, Lamb L, Gee A, Henslee-Downey PJ. Immunotherap with donor leukocyte infusions for patients with relapsed acute myeloid leukemia following partially mismatched related donor bone marrow transplantation. Bone Marrow Transplantation, 1995; 15: 979–981.

    PubMed  CAS  Google Scholar 

  64. Porter D, Collins R, Mick R, Kernan N, Giralt S, Flowers M, Casper J, Drobyski W, Leahey A, Parker P, Bates B, King R, Antin J. Unrelated donor leukocyte infusions to treat relapse or EBV-lymphoproliferative disease after unrelated donor bone marrow transplantation. Blood 1998: 90: 590a.

    Google Scholar 

  65. Porter DL, Collins R, Drobyski W, Connors JM, Van Hoef M, Antin J Long term follow up of 55 patients who received complete remission aftei donor leukocyte infusions for relapse after allogeneic bone marrow transplantation. Blood 1997; 90: 549a.

    Google Scholar 

  66. Korngold R, Sprent J. Variable capacity of L3T4+ T cells to cause lethal graft-versus-host disease across minor histocompatibility barriers in mice Journal of Experimental Medicine, 1987; 165: 1552–1564.

    Article  PubMed  CAS  Google Scholar 

  67. Drobyski WR, Majewski D, Ozker K, Hanson G. Ex vivo anti-CD3 antibody-activated donor T cells have a reduced ability to cause letha murine graft-versus-host disease but retain their ability to facilitate alloengraftment. Journal of Immunology, 1998; 161(5): 2610–2619.

    CAS  Google Scholar 

  68. Truitt RL, Atasoylu AA. Contribution of CD4+ and CD8+ T cells to graft-versus-host disease and graft-versus-leukemia reactivity after transplantation of MHC-compatible bone marrow. Bone Marrow Transplantation, 1991; 8: 51–58.

    PubMed  CAS  Google Scholar 

  69. Giralt S, Hester J, Huh Y, Hirsch-Ginsberg C, Rondon G, Seong D, Lee M Gajewski J, Van Besien K, Khouri I, Mehra R, Przepiorka D, Korbling M, Talpaz M, Kantarjian H, Fischer H, Deisseroth A, Champlin R. CD8-depleted donor lymphocyte infusion as treatment for relapsed chronic myelogenous leukemia after allogeneic bone marrow transplantation. Blood, 1995:86,11: 4337–4343.

    PubMed  CAS  Google Scholar 

  70. Helene M, Lake-Bullock V, Bryson JS, Jennings CD, Kaplan AM. Inhibition of graft-versus-host disease: Use of a T cell-controlled suicide gene. Journal of Immunology, 1997; 158: 5079–5082.

    CAS  Google Scholar 

  71. Cohen JL, Boyer O, Salomon B, Onclercq R, Charlotte F, Bruel S, Boisserie G, Klatzmann D. Prevention of graft-versus-host disease in mice using a suicide gene expressed in T lymphocytes. Blood, 1997; 89: 4636–4645.

    PubMed  CAS  Google Scholar 

  72. Bonini C, Ferrari G, Verzeletti S, Servida P, Zappone E, Ruggieri L, Ponzoni M, Rossini S, Mavilio F, Traversari C, Bordignon C. HSV-TK gene transfer into donor lymphocytes for control of allogeneic graft-versus-leukemia. Science, 1997; 276: 1719–1724.

    Article  PubMed  CAS  Google Scholar 

  73. Slavin S, Naparstek E, Nagler A, Ackerstein A, Kapelushnik J, Or R. Allogeneic cell therapy for relapsed leukemia after bone marrow transplantation with donor peripheral blood lymphocytes. Experimental Hematology, 1995; 23: 1553–1562.

    PubMed  CAS  Google Scholar 

  74. Naparstek E, Or R, Nagler A, Cividalli G, Engelhard D, Aker M, Gimon Z, Manny N, Sacks T, Tochner Z, Weiss L, Samuel S, Brautbar C, Hale G, Waldmann H, Steinberg SM, Slavin S. T-cell-depleted allogeneic bone marrow transplantation for acute leukaemia using campath-1 antibodies and post-transplant administration of donor’s peripheral blood lymphocytes for prevention of relapse. British Journal of Haematology, 1995; 89: 506–515.

    Article  PubMed  CAS  Google Scholar 

  75. Barrett AJ, Mavroudis D, Tisdale J, Molldrem J, Clave E, Dunbar C, Cottier-Fax M, Phang S, Carter C, Okunnieff P, Young NS, Read EJ. T cell-depleted bone marrow transplantation and delayed T cell add-back to control acute GVHD and conserve a graft-versus-leukemia effect. Bone Marrow Transplantation, 1998; 21: 543–551.

    Article  PubMed  CAS  Google Scholar 

  76. Giralt S, Estey E, Albitar M, van Besien K, Rondon G, Anderlini P, O’Brien S, Khouri I, Gajewski J, Mehra R, Claxton D, Andersson B, Beran M, Przepiorka D, Koller C, Kornblau S, Korbling M, Keating M, Kantarjian H, Champlin R. Engraftment of allogeneic hematopoietic progenitor cells with purine analog-containing chemotherapy: Harnessing graft-versus-leukemia without myeloablative therapy. Blood 1997; 89: 4531–4536.

    PubMed  CAS  Google Scholar 

  77. Slavin S, Nagler A, Naparstek E, Kapelushnik Y, Aker M, Cividalli, Varadi G, Kirschbaum M, Ackerstein A, Samuel S, Amar A, Brautbar C, Ben-Tal O, Eldor A, Or R. Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematologic diseases. Blood, 1998; 91: 756–763.

    PubMed  CAS  Google Scholar 

  78. Datta AR, Barrett AJ, Jiang YZ, Guimaraes A, Mavroudis DA, van Rhee F, Gordon AA, Madrigal A. Distinct T cell populations distinguish chronic myeloid leukaemia cells from lymphocytes in the same individual: a model for separating GVHD from GVL reactions. Bone Marrow Transplantation, 1994;14: 517–524.

    PubMed  CAS  Google Scholar 

  79. De Bueger M, Bakker A, Van Rood JJ, Van Der Woude F, Goulmy E. Tissue distribution of human minor histocompatibility antigens. Ubiquitous versus restricted tissue distribution indicates heterogeneity among human cytotoxic T lymphocyte-defined non-MHC antigens. Journal of Immunology, 1992; 149: 1788–1794.

    Google Scholar 

  80. Molldrem JJ, Clave E, Jiang YZ, Mavroudis D, Raptis A, Hensel N, Agarwala V, Barrett AJ. Cytotoxic T lymphocytes specific for a nonpolymorphic proteinase 3 peptide preferentially inhibit chronic myeloid leukemia colony-forming units. Blood, 1997; 90,7: 2529–2534.

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Medicine and the Bone Marrow Transplant Program, Medical College of Wisconsin, Milwaukee, WI, 53226, USA

    William R. Drobyski

Authors
  1. William R. Drobyski
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Northwestern University Medical Center, Chicago, USA

    Richard K. Burt  & Mary M. Brush  & 

Rights and permissions

Reprints and permissions

Copyright information

© 1999 Springer Science+Business Media New York

About this chapter

Cite this chapter

Drobyski, W.R. (1999). Adoptive Immunotherapy Using Donor Leukocyte Infusions to Treat Relapsed Hematologic Malignancies after Allogeneic Bone Marrow Transplantation. In: Burt, R.K., Brush, M.M. (eds) Advances in Allogeneic Hematopoietic Stem Cell Transplantation. Cancer Treatment and Research, vol 101. Springer, Boston, MA. https://doi.org/10.1007/978-1-4615-4987-1_11

Download citation

  • DOI: https://doi.org/10.1007/978-1-4615-4987-1_11

  • Publisher Name: Springer, Boston, MA

  • Print ISBN: 978-1-4613-7264-6

  • Online ISBN: 978-1-4615-4987-1

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation